WO2007018818A1 - A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor - Google Patents
A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor Download PDFInfo
- Publication number
- WO2007018818A1 WO2007018818A1 PCT/US2006/025377 US2006025377W WO2007018818A1 WO 2007018818 A1 WO2007018818 A1 WO 2007018818A1 US 2006025377 W US2006025377 W US 2006025377W WO 2007018818 A1 WO2007018818 A1 WO 2007018818A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridin
- methyl
- quinolin
- pyrrolo
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- TGF- ⁇ Transforming growth factor-beta
- TGF- ⁇ family members activate transmembrane serine/threonine receptor kinases, thereby initiating a signaling cascade via S mads, a novel class of intracellular signaling effectors that regulate gene expression.
- TGF- ⁇ is a potent inducer of growth arrest in many cell types, including epithelial cells. This activity is the basis of the tumor suppressor role of the TGF- ⁇ signaling system in carcinomas. Other activities, including TGF- ⁇ -induced epithelial-to- mesenchymal differentiation, contribute to cancer progression.
- TGF- ⁇ family signaling is of special relevance in mesenchymal differentiation, including bone development. Deregulated expression or activation of components of this signaling system can contribute to skeletal diseases, e.g. osteoarthritis. See Wakefield, et al. (2002) Current Opinion in Genetics & Development 12:22-29; Siegel, et al. (2003) Nature Reviews (Cancer) 3:807-820; Dumont, et al. (2003) Cancer Cell 3:531-536.
- PCT patent application WO 02/0948332 describes a genus of dihydropyrrolopyrazole compounds useful for treating disorders associated with enhanced TGF- ⁇ signaling activity or overproduction.
- PCT patent application WO 04/04382 describes an anhydrous form of 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6- dihydro-4H-pyrrolo [ 1 ,2-b] ⁇ yrazole.
- the present invention provides 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4- yl)-5,6-dihydro-4H ⁇ pyrrolo[l,2-b]pyrazole monohydrate, i.e., Formula I.
- the present invention provides 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4- yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate in a crystalline form.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising 2-(6- methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate and a pharmaceutically acceptable excipient, diluent or carrier.
- the present invention provides a method of inhibiting TGF- ⁇ signaling in a mammal comprising administering to a mammal in need of such treatment an effective amount of 2-(6-methyl-pyri din-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H- pyrrolo[l,2-b]pyrazole monohydrate.
- the present invention further provides a method of treating conditions resulting from excessive TGF- ⁇ production in a mammal comprising administering to a mammal in need of such treatment a TGF- ⁇ signal-suppressing amount of 2-(6-methyl-pyridin-2-yl)- 3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate. Because the compounds of the present invention are inhibitors of TGF- ⁇ signaling, the compounds of the present invention are useful for the treatment of a variety of disorders including the treatment of susceptible neoplasms.
- this invention is directed to a method for treating susceptible neoplasms comprising administering to a patient in need thereof an effective amount of 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H- pyrrolo [ 1 ,2-b]pyrazole monohydrate.
- the present invention provides 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4- yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate for use in therapy.
- the present invention provides for the use of 2-(6-methyl-pyridin-2-yl)-3-[6-arnido-quinolin-4-yl)- 5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate for the manufacture of a medicament for the treatment of disorders associated with enhanced TGF- ⁇ signaling activity or overproduction.
- this invention provides a process for making 2-(6-methyl- pyridin-2-yl)-3-[6-amido-quinolin-4-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate and novel intermediates useful for making crystalline 2-(6-methyl-pyridin- 2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate: 6- cyano-4-methyl-quinoline hydrochloride, 2 ⁇ (6-cyano-quinolin-4-yl) ⁇ l-(6-methyl-pyridin- 2-yl)-ethanone; l-amino)-2-pyrrolidinone, p-toluene sulfonate; l-[(6-methyl-pyridin-2- yl)-2-(6-cyano-quinolin-4-yl)-ethyliden
- an effective amount of a compound of the present invention refers to an amount, that is, the dosage which is effective in treating the disorders described herein.
- an effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances.
- the dose of a compound of the present invention a number of factors are considered by the attending diagnostician, including, but not limited to: the compound of the present invention to be administered; the co-administration of other therapies, if used; the species of mammal; its size, age, and general health; the specific disorder involved; the degree of involvement or the severity of the disorder; the response of the individual patient; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of other concomitant medication; and other relevant circumstances.
- An effective amount of a compound of the present invention is expected to be delivered QD or BID at 10 mg to 1 g total daily dose, preferably from 100-200 mg preferred flat dose.
- An effective amount could also be once a day or once a week dosing with sustained release formulations. More preferred amounts can be determined by one skilled in the art.
- TGF- ⁇ includes both TGF- ⁇ l and TGF- ⁇ 2.
- Conditions "characterized by enhanced TGF- ⁇ activity" include those wherein TGF- ⁇ synthesis is stimulated so that TGF- ⁇ is present at increased levels or wherein TGF- ⁇ latent protein is undesirably activated or converted to active TGF- ⁇ protein or wherein TGF- ⁇ receptors are upregulated or wherein the TGF- ⁇ protein shows enhanced binding to cells or extracellular matrix in the location of the disease.
- enhanced activity refers to any condition wherein the biological activity of TGF- ⁇ is undesirably high, regardless of the cause.
- TGF- ⁇ 1 produced by the tumor may be deleterious.
- prostrate cancer e.g., Steiner and Barrack (1992) MoI. Endocrinol 6:15-25
- colorectal cancer e.g., Neurath et al. (2004) Immunity. 21:491-501
- breast cancer e.g.,Arteaga, et al. (1993) Cell Growth and Differ. 4: 193-201
- non-small cell lung cancer e.g., Ready et al., (Apr 2005) Semin
- ovarian cancer e.g., Dr. Gustavo C. Rodriguez, (March 2- 7, 2001) 32nd Annual Meeting of the Society of Gynecologic Oncologists. Nashville, TN
- endometrial cancer e.g., Dowdy et al, (Feb 2005) Gynecol Oncol. 96(2):368-73
- testicular cancer e.g., Morera et al., (1992) Endocrinology. 130:831-836
- osteosarcoma e.g., Kloen et al., (Aug 1, 1994) Int J Cancer.
- Another embodiment of the present invention is the crystalline monohydrate form of 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[l,2- b]pyrazole. This compound has been characterized as described below.
- a properly prepared sample of 2-(6-methyl-pyridin-2-yl)-3-[6 ⁇ amido- quinolin-4-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate may be characterized by X-ray diffraction pattern using CuK ⁇ radiation as having diffraction peaks (2-theta values) as described in Table 1, and in particular having peaks at 9.05 in combination with one or more of the peaks at 11.02, 11.95, and 14.84; and more particularly having a peak at 9.05; with a tolerance for the diffraction angles of 0.1 degrees, more preferably .01 degrees.
- 4H-pyrrolo[l,2-b]pyrazole monohydrate may be characterized by solid state 13 C nuclear magnetic resonance having chemical shift (ppm) of 108.8, 115.6, 122.6, and 171.0 (+/- 0.2) ppm.
- this invention provides a process for preparing 2-(6- methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate comprising crystallizing 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4- yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole from an appropriate solvent containing an organic solvent to water ratio of 0-90% under conditions which yield 2-(6-methyl- pyridin-2-yl)-3-[6-amido-quinolin-4-yl-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate.
- 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl-5,6-dihydro-4H-pyrrolo[l,2- b]pyrazole monohydrate may be prepared by crystallization under controlled conditions.
- the monohydrate of the present invention can be prepared by crystallization from an aqueous solvent.
- a suitable solvent is one that has an organic solvent to water ratio of 0-90% organic solvent.
- Preferred is an organic solvent to water ratio between 60:40 to 85: 15. More preferred is an organic solvent to water ratio of 75:25.
- Preferred organic solvents are acetonitrile, acetone, tetrahydrafuran (THF), methyl ethyl ketone, dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), N,N-dimethyl acetamide, and N-methyl pyrrolidinone.
- THF tetrahydrafuran
- DMSO dimethyl sulfoxide
- DMF dimethyl formamide
- N,N-dimethyl acetamide N-methyl pyrrolidinone
- acetone is most preferred.
- the volume of the resulting solution is reduced, preferably by distillation, to between 35-70% of the initial volume, preferably 50%.
- an appropriate amount of additional water may need to be added to precipitate the product.
- seed crystals of monohydrate may be added.
- Slowly cool the solution to 0-5 0 C preferably in two stages wherein the solution is first cooled to 20-25 0 C over 90 minutes followed by cooling to 0- 5 0 C over 30-40 minutes. Hold the slurry at 0-5 °C for an additional 30 minutes to 25 hours, preferably 2-3 hours. Filter the slurry and rinse the product, preferably with water or aqueous organic solvent. Dry the product, preferably at 45 0 C.
- 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6- dihydro-4H-pyrrolo[l,2-b]pyrazole monohydrate can be prepared by reslurrying 2-(6- methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole in water or aqueous DMSO.
- 2-(6-Methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl-5,6-dihydro-4H-pyrrolo[l,2- b]pyrazole monohydrate may be prepared by stirring in 10 volumes of 0-90% organic solvent to water at room temperature for 1-2 hours, filtering, and drying at 35-45 0 C, preferably 45 0 C under vacuum. In cases where organic solvent is used, the reaction mixture may be diluted with water (2-5 times the volume of organic solvent used) to improve recovery.
- Crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H- pyrrolo[l,2-b]pyrazole monohydrate can be prepared by a variety of procedures, some of which are illustrated in the examples below. It will be recognized by one of skill in the art that the order of the individual steps in the following may be varied to provide crystalline 2-(6-methyl-pyridin-2-yl)-3- [6-amido-quinolin-4-yl)-5 ,6-dihydro-4H- pyrrolo[ 1 ,2-b]pyrazole monohydrate:
- Step 1 Preparation of 6-cyano-4-methyl-quinoline hydrochloride.
- Step 3b and 3c Preparation of intermediates l-[(6-methyl-pyridin-2-yl)-2-(6-cyano- quinolin-4-yl)-ethylideneamino]-pyrrolidin-2-one and 3-(6-cyano-quinolin-4-yl)-2-(6- methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole.
- Step 4 Preparation of 2-(6-methyl-pyridin-2-yl)-3-(6-amido-quinolin-4-yl)-5,6-dihydro- 4H-pyrrolo[l,2-b]pyrazole, monohydrate.
- the monohydrate of the present invention can be prepared by recrystallization of 2-(6-Methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H- pyrrolo[l,2-b]pyrazole.
- the monohydrate of the present invention can be prepared by reslurrying of 2-(6-Methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl) ⁇ 5,6-dihydro-4H- pyrrolo [ 1 ,2-b]pyrazole.
- the 6X-HIS tagged cytoplasmic kinase domain of each receptor was expressed and purified from Sf9 insect cell lysates as briefly described below:
- IX KB (50 mM Tris pH 7.5, 150 mM NaCl, 4 mM MgCl 2 , 1 mM NaF, 2 mM ⁇ -mercaptoethanol), elute with a linear gradient of IX KB containing 200 mM Imidazole. Both enzymes were approximately 90% pure and had autophosphorylation activity. Reactions: 170-200 nM enzyme in IX KB, compound dilution series in IX
- Reactions are incubated at 30 0 C for 1 hour. Reactions are stopped and quantitated using standard TCA/BSA precipitation onto Millipore FB glass fiber filter plates and by liquid scintillation counting on a MicroBeta JET.
- the compound disclosed herein inhibits the TGF- ⁇ l Type I (RIT204D) receptor kinase domain with an IC50 value of 56 nM.
- the compounds of the present invention are preferably formulated as pharmaceutical compositions administered by a variety of routes. Most preferably, such compositions are for oral administration.
- Such pharmaceutical compositions and processes for preparing same are well known in the art. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro, et al., ed., 19 th ed., Mack Publishing Co., 1995).
- the compounds of the present invention are generally effective over a wide dosage range.
- dosages per day normally fall within the range of about 0.0001 to about 30 mg/kg of body weight.
- dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage range is not intended to limit the scope of the invention in any way.
- the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK06774280.9T DK1910370T3 (en) | 2005-07-22 | 2006-06-29 | PYRIDINQUINOLINE SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR |
MX2008001020A MX2008001020A (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor. |
RS20150319A RS53999B1 (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo (1,2-b) pyrazole monohydrate as tgf-beta inhibtor |
BRPI0613639-7A BRPI0613639A2 (en) | 2005-07-22 | 2006-06-29 | compound, pharmaceutical composition, use of the compound, and process for producing a compound |
EP20060774280 EP1910370B1 (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
US11/995,938 US7872020B2 (en) | 2005-07-22 | 2006-06-29 | TGF-β inhibitors |
SI200631924T SI1910370T1 (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo (1,2-b) pyrazole monohydrate as tgf-beta inhibitor |
JP2008522796A JP5242391B2 (en) | 2005-07-22 | 2006-06-29 | Pyridinequinoline substituted pyrrolo [1,2-B] pyrazole monohydrate as a TGF-beta inhibitor |
PL06774280T PL1910370T3 (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
CA2616196A CA2616196C (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
ES06774280.9T ES2542425T3 (en) | 2005-07-22 | 2006-06-29 | Pyrrolo [1,2-b] pyrazole substituted pyridinoquinoline monohydrate as a TBF-beta inhibitor |
IL188181A IL188181A (en) | 2005-07-22 | 2007-12-17 | 2-(6-methyl-pyridin-2-yl)-3-(6-amido-quinolin-4-yl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole monohydrate as anti-cancer medicament and pharmaceutical compositions comprising it |
HRP20150474TT HRP20150474T1 (en) | 2005-07-22 | 2015-05-04 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70164105P | 2005-07-22 | 2005-07-22 | |
US60/701,641 | 2005-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007018818A1 true WO2007018818A1 (en) | 2007-02-15 |
Family
ID=37450942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/025377 WO2007018818A1 (en) | 2005-07-22 | 2006-06-29 | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
Country Status (16)
Country | Link |
---|---|
US (1) | US7872020B2 (en) |
EP (1) | EP1910370B1 (en) |
JP (1) | JP5242391B2 (en) |
BR (1) | BRPI0613639A2 (en) |
CA (1) | CA2616196C (en) |
DK (1) | DK1910370T3 (en) |
ES (1) | ES2542425T3 (en) |
HR (1) | HRP20150474T1 (en) |
HU (1) | HUE025209T2 (en) |
IL (1) | IL188181A (en) |
MX (1) | MX2008001020A (en) |
PL (1) | PL1910370T3 (en) |
PT (1) | PT1910370E (en) |
RS (1) | RS53999B1 (en) |
SI (1) | SI1910370T1 (en) |
WO (1) | WO2007018818A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011124539A1 (en) | 2010-04-07 | 2011-10-13 | Bayer Cropscience Ag | Bicyclic pyrimidinyl pyrazoles |
WO2013009140A3 (en) * | 2011-07-13 | 2013-04-11 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
WO2014072517A1 (en) | 2012-11-12 | 2014-05-15 | Institució Catalana De Recerca I Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
WO2016160881A1 (en) | 2015-04-01 | 2016-10-06 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
WO2017106291A1 (en) | 2015-12-15 | 2017-06-22 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
WO2018006870A1 (en) * | 2016-07-07 | 2018-01-11 | 苏州科睿思制药有限公司 | Galunisertib crystal form and preparation method therefor and use thereof |
WO2018068759A1 (en) | 2016-10-14 | 2018-04-19 | 江苏恒瑞医药股份有限公司 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof |
US10041047B2 (en) | 2013-03-14 | 2018-08-07 | Massachusetts Institute Of Technology | Compositions and methods for epithelial stem cell expansion and culture |
WO2019042383A1 (en) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Crystalline forms of galunisertib, preparation method therefor, and use thereof |
WO2019105217A1 (en) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Crystal form of galunisertib and preparation method therefor and use thereof |
WO2019137027A1 (en) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Crystal form of galunisertib and preparation method and use thereof |
WO2019183245A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
WO2019236766A1 (en) | 2018-06-06 | 2019-12-12 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
US10568883B2 (en) | 2014-09-03 | 2020-02-25 | Massachusetts Institute Of Technology | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
WO2020142485A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
US11033546B2 (en) | 2016-03-02 | 2021-06-15 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: I |
US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
US11160868B2 (en) | 2016-03-02 | 2021-11-02 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11162071B2 (en) | 2018-08-17 | 2021-11-02 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating JAG-1 |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
CN115282280A (en) * | 2022-08-12 | 2022-11-04 | 中国科学技术大学 | New use of TGF-beta 1 signal inhibitor |
US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110582497B (en) * | 2017-03-17 | 2022-03-11 | 杭州领业医药科技有限公司 | Crystal form of Galunertib, preparation method and pharmaceutical composition thereof |
WO2018170724A1 (en) | 2017-03-21 | 2018-09-27 | 杭州领业医药科技有限公司 | Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4h-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094833A1 (en) * | 2001-05-24 | 2002-11-28 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
WO2004048382A1 (en) * | 2002-11-22 | 2004-06-10 | Eli Lilly And Company | Quinolinyl-pyrrolopyrazoles |
WO2004048383A1 (en) * | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
-
2006
- 2006-06-29 PL PL06774280T patent/PL1910370T3/en unknown
- 2006-06-29 US US11/995,938 patent/US7872020B2/en not_active Expired - Fee Related
- 2006-06-29 EP EP20060774280 patent/EP1910370B1/en active Active
- 2006-06-29 JP JP2008522796A patent/JP5242391B2/en not_active Expired - Fee Related
- 2006-06-29 CA CA2616196A patent/CA2616196C/en not_active Expired - Fee Related
- 2006-06-29 ES ES06774280.9T patent/ES2542425T3/en active Active
- 2006-06-29 WO PCT/US2006/025377 patent/WO2007018818A1/en active Application Filing
- 2006-06-29 MX MX2008001020A patent/MX2008001020A/en active IP Right Grant
- 2006-06-29 DK DK06774280.9T patent/DK1910370T3/en active
- 2006-06-29 RS RS20150319A patent/RS53999B1/en unknown
- 2006-06-29 HU HUE06774280A patent/HUE025209T2/en unknown
- 2006-06-29 SI SI200631924T patent/SI1910370T1/en unknown
- 2006-06-29 PT PT67742809T patent/PT1910370E/en unknown
- 2006-06-29 BR BRPI0613639-7A patent/BRPI0613639A2/en not_active Application Discontinuation
-
2007
- 2007-12-17 IL IL188181A patent/IL188181A/en not_active IP Right Cessation
-
2015
- 2015-05-04 HR HRP20150474TT patent/HRP20150474T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094833A1 (en) * | 2001-05-24 | 2002-11-28 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
WO2004048383A1 (en) * | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
WO2004048382A1 (en) * | 2002-11-22 | 2004-06-10 | Eli Lilly And Company | Quinolinyl-pyrrolopyrazoles |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8507472B2 (en) | 2010-04-07 | 2013-08-13 | Bayer Cropscience Ag | Bicyclic pyridinylpyrazoles |
WO2011124539A1 (en) | 2010-04-07 | 2011-10-13 | Bayer Cropscience Ag | Bicyclic pyrimidinyl pyrazoles |
RU2612958C2 (en) * | 2011-07-13 | 2017-03-14 | Ск Кемикалз Ко., Лтд. | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
WO2013009140A3 (en) * | 2011-07-13 | 2013-04-11 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
CN103764655A (en) * | 2011-07-13 | 2014-04-30 | Sk化学公司 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
US10155763B2 (en) | 2011-07-13 | 2018-12-18 | Tiumbio Co., Ltd. | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
CN103764655B (en) * | 2011-07-13 | 2017-04-12 | Sk化学公司 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
WO2014072517A1 (en) | 2012-11-12 | 2014-05-15 | Institució Catalana De Recerca I Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
US10954490B2 (en) | 2013-03-14 | 2021-03-23 | The Brigham And Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion and culture |
US10041047B2 (en) | 2013-03-14 | 2018-08-07 | Massachusetts Institute Of Technology | Compositions and methods for epithelial stem cell expansion and culture |
US10041046B2 (en) | 2013-03-14 | 2018-08-07 | Massachusetts Institute Of Technology | Compositions and methods for epithelial stem cell expansion and culture |
US11369607B2 (en) | 2014-09-03 | 2022-06-28 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
US10568883B2 (en) | 2014-09-03 | 2020-02-25 | Massachusetts Institute Of Technology | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
WO2016160881A1 (en) | 2015-04-01 | 2016-10-06 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
WO2017106291A1 (en) | 2015-12-15 | 2017-06-22 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
US11033546B2 (en) | 2016-03-02 | 2021-06-15 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: I |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US11160868B2 (en) | 2016-03-02 | 2021-11-02 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
EP4049665A1 (en) | 2016-03-15 | 2022-08-31 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
WO2018006870A1 (en) * | 2016-07-07 | 2018-01-11 | 苏州科睿思制药有限公司 | Galunisertib crystal form and preparation method therefor and use thereof |
US10604528B2 (en) | 2016-07-07 | 2020-03-31 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Galunisertib crystalline form, preparation method thereof and use thereof |
WO2018068759A1 (en) | 2016-10-14 | 2018-04-19 | 江苏恒瑞医药股份有限公司 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof |
US10906905B2 (en) | 2016-10-14 | 2021-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof |
US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
WO2019042383A1 (en) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Crystalline forms of galunisertib, preparation method therefor, and use thereof |
WO2019105217A1 (en) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Crystal form of galunisertib and preparation method therefor and use thereof |
WO2019105082A1 (en) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Crystal form of galunisertib and preparation method therefor and use thereof |
WO2019137027A1 (en) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Crystal form of galunisertib and preparation method and use thereof |
WO2019183245A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
WO2019236766A1 (en) | 2018-06-06 | 2019-12-12 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
US11162071B2 (en) | 2018-08-17 | 2021-11-02 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating JAG-1 |
US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
WO2020142485A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
CN115282280A (en) * | 2022-08-12 | 2022-11-04 | 中国科学技术大学 | New use of TGF-beta 1 signal inhibitor |
Also Published As
Publication number | Publication date |
---|---|
EP1910370A1 (en) | 2008-04-16 |
CA2616196C (en) | 2012-08-21 |
US7872020B2 (en) | 2011-01-18 |
US20100120854A1 (en) | 2010-05-13 |
IL188181A0 (en) | 2008-03-20 |
PT1910370E (en) | 2015-06-30 |
RS53999B1 (en) | 2015-10-30 |
SI1910370T1 (en) | 2015-06-30 |
JP5242391B2 (en) | 2013-07-24 |
HUE025209T2 (en) | 2016-03-29 |
ES2542425T3 (en) | 2015-08-05 |
BRPI0613639A2 (en) | 2012-02-22 |
EP1910370B1 (en) | 2015-04-22 |
DK1910370T3 (en) | 2015-06-08 |
CA2616196A1 (en) | 2007-02-15 |
PL1910370T3 (en) | 2015-09-30 |
MX2008001020A (en) | 2008-03-25 |
IL188181A (en) | 2014-05-28 |
JP2009502780A (en) | 2009-01-29 |
HRP20150474T1 (en) | 2015-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1910370B1 (en) | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor | |
JP6430512B2 (en) | Inhibitors of lysine-specific demethylase-1 | |
AU2008252380B2 (en) | Quinazolin-oxime derivatives as Hsp90 inhibitors | |
DK3037424T3 (en) | NEW QUINOLIN-SUBSTITUTED COMPOUND | |
US10017513B2 (en) | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | |
RU2633694C2 (en) | Dyetherned phenylaminopyrimidine and pharmaceutical composition containing such connection | |
KR20200004871A (en) | Thienopyridine and Benzothiophene Useful as IRAK4 Inhibitors | |
JP6268276B2 (en) | Novel N (2,3-dihydro-1H-pyrrolo [2,3-b] pyridin-5-yl) -4-quinazolinamine derivatives and N- (2,3-dihydro-1H-indoles as PERK inhibitors -5-yl) -4-quinazolineamine derivatives | |
EP2985277A1 (en) | Dipyrromethene crystal and method for manufacturing same | |
HUE029343T2 (en) | Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof | |
CN111542522B (en) | Substituted pyrazolopyrimidines useful as kinase inhibitors | |
EP4137484A1 (en) | Tricyclic compounds as egfr inhibitors | |
UA54449C2 (en) | 3-substituted pyrido[4,3':4,5]thieno-[2,3-d]pyrimidine derivatives, preparation and use thereof | |
EP3434674B1 (en) | ((4-(2-oxoimidazolidine-1-yl)pyrimidin-2-yl)amine derivatives as mutant idh inhibitors for treating cancer | |
CN112823159B (en) | Aromatic heterocyclic compounds with kinase inhibitory activity | |
AU2018337138B2 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
WO2019141096A1 (en) | Substituted urea compound and preparation method and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 188181 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008522796 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 110/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006774280 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11995938 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2616196 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/001020 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: PI0613639 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080122 |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2015/0319 Country of ref document: RS |